Lilly to be China's 'fastest-growing' pharma without M&A if new launches follow Cialis' success
This article was originally published in Scrip
Executive Summary
Eli Lilly has become the latest firm to join a wave of expansion by global pharma companies in China. At a media roundtable in Beijing, chairman, president and CEO John Lechleiter revealed that the company is planning to launch at least a dozen new drugs in the country over the next five years.
You may also be interested in...
Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
China's new biosimilars guideline: more flexibility, but stricter in parts
The China Food and Drug Administration has released the final version of its biosimilars guideline1.